MERIDIAN BIOSCIENCE, INC. Inactive Instrument
Meridian Bioscience, Inc. Stock
Equities
VIVO
US5895841014
Medical Equipment, Supplies & Distribution
More news
More recommendations
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | 45 | 22-02-20 | |
Charles Wood
IRC | Investor Relations Contact | - | 19-12-31 |
Julie Smith
AUD | Comptroller/Controller/Auditor | 56 | 20-02-29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | 45 | 22-02-20 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.25% | 43 M€ | -2.53% | - | |
| 0.29% | 27 M€ | -4.62% | - | |
| 0.14% | 0 M€ | 0.00% | - | |
| 0.14% | 0 M€ | 0.00% | - |
Meridian Bioscience, Inc. is a life science company. The Company is engaged in the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, specialized polymerase chain reaction (PCR) master mixes, and bioresearch reagents used by other diagnostic test manufacturers and researchers in immunological and molecular tests for human, animal, plant and environmental applications. The Company's segments include Diagnostics and Life Science. The Diagnostics segment consists of manufacturing operations for infectious disease products in Cincinnati, Ohio; Quebec City, Canada; and Modi'in, Israel. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; and Luckenwalde, Germany.
| 1st Jan change | Capi. | |
|---|---|---|
| -0.25% | 189B | |
| -1.82% | 106B | |
| -2.89% | 67.94B | |
| +9.92% | 52.48B | |
| +14.65% | 46.63B | |
| -3.43% | 38.9B | |
| +8.82% | 27.82B | |
| +3.56% | 26.97B | |
| +6.30% | 25.94B |
